Bicara Therapeutics Quarterly Cash Flow Statement
NASDAQ: BCAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
17.50+0.24 (+1.39%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bicara Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Bicara Therapeutics generated -$44.2 million of operating cash flow and spent $60,000 on capital expenditures. That left free cash flow of -$44.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
Bicara Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -55.44M | -56.21M | -37.39M | -36.33M | -27.39M | -36.85M | -20.96M | -17.48M | -17.05M | -12.51M | -12.44M | -22.84M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 44.00K | 44.00K | 43.00K | 24.00K | 19.00K | 19.00K | 15.00K | 15.00K | 13.00K | 13.00K | 14.00K | — |
| Stock-Based Compensation | 8.24M | 5.86M | 4.45M | 3.61M | 3.49M | 3.45M | 3.18M | 2.03M | 1.04M | 1.15M | 765.00K | 519.00K |
| Change in Working Capital | -1.40M | 2.09M | 839.00K | -301.00K | 627.00K | 4.12M | -16.57M | -108.00K | 63.00K | -235.00K | -59.00K | — |
| Operating Cash Flow | -44.21M | -37.51M | -23.89M | -29.25M | -25.59M | -28.11M | -30.03M | -17.22M | -12.91M | -14.59M | -8.04M | — |
| Capital Expenditures | -60.00K | -60.00K | -238.00K | -42.00K | 0 | 0 | -40.00K | -8.00K | -19.00K | -4.00K | -436.00K | — |
| Investing Cash Flow | -184.99M | 100.94M | -82.33M | -236.12M | 0 | 0 | -40.00K | -8.00K | -19.00K | 58.00K | -436.00K | — |
| Financing Cash Flow | 2.33M | 163.34M | 31.23M | 436.00K | 135.00K | 460.00K | -975.00K | 334.13M | 734.00K | 137.00K | 194.70M | — |
| Net Change in Cash | -226.86M | 226.78M | -74.99M | -264.93M | -25.46M | -27.65M | -31.05M | 316.90M | -12.19M | -14.39M | 186.23M | — |
| Free Cash Flow | -44.27M | -37.57M | -24.12M | -29.29M | -25.59M | -28.11M | -30.07M | -17.23M | -12.93M | -14.59M | -8.47M | — |
This table shows 12 quarterly periods of Bicara Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BCAX's reporting calendar. What is a cash flow statement?